CellCentric is a technology company.
CellCentric has raised $155.0M across 2 funding rounds.
CellCentric has raised $155.0M in total across 2 funding rounds.
CellCentric is a clinical-stage biopharmaceutical company developing inobrodib (CCS1477), a first-in-class oral p300/CBP inhibitor targeting gene regulation in cancer cells, primarily for multiple myeloma and other solid tumors and hematological malignancies.[1][2][3] The company serves cancer patients by addressing unmet needs in gene regulation-driven cancers, where dysregulated chromatin mechanisms lead to uncontrolled cell growth; inobrodib disrupts these pathways to halt tumor progression.[1][2] Now in Phase II trials across the UK, US, and EU, CellCentric has raised $253.9M in funding, including a $120M round recently, signaling strong growth momentum amid advancing clinical validation.[4]
(Note: Search results also reference a separate entity, cellcentric—a 2021 Daimler Truck/Volvo JV focused on hydrogen fuel cells for heavy-duty vehicles—but the query specifies "CellCentric" as a technology company matching the biotech profile; fuel cell references are distinct and not core here.[5][6][7])
CellCentric originated as a 2003 spinout from the University of Cambridge, co-founded by pioneering developmental biologist Professor Azim Surani FRS, CBE from the Gurdon Institute, who discovered inherited epigenetic codes beyond DNA that control cell fate.[1][4] Surani's work revealed how chromatin-related mechanisms—enzymes modifying DNA and histones—could be disrupted in cancer, inspiring the company's focus on novel drug targets.[1] Early efforts built a global network with over 25 academic groups, screening 50+ targets; programs like an arginine methyltransferase were licensed to Takeda, paving the way to prioritize p300/CBP inhibition with inobrodib, now in Phase II.[1][3]
CellCentric rides the epigenetics and precision oncology wave, targeting gene regulation "writers" like p300/CBP—underexplored versus DNA-focused therapies amid rising multiple myeloma incidence and resistance to standards like proteasome inhibitors.[1][2] Timing aligns with biotech's shift to oral, mechanism-novel drugs for hematological cancers, bolstered by academic-industry networks de-risking targets; market forces include aging populations driving demand and Big Pharma interest (e.g., prior Takeda deal).[1][4] It influences the ecosystem by validating chromatin modulation, inspiring similar epigenetic pursuits and advancing patient outcomes through collaborative trials.[3]
Phase II data readouts for inobrodib in multiple myeloma could catalyze partnerships or approval by late 2020s, expanding to combos with standards like IMiDs; sustained funding positions it for Phase III.[1][4] Trends like AI-aided target discovery and epigenetic combos will amplify impact, potentially evolving CellCentric into a multi-asset oncology leader transforming hard-to-treat cancers.[2][3] This science-rooted innovator exemplifies biotech's power to decode cell fate for patients.
CellCentric has raised $155.0M in total across 2 funding rounds.
CellCentric's investors include ARCH Venture Partners, Atlas Venture, Forbion, Krishna Yeshwant, HealthCap, INKEF Capital, Pfizer Venture Investments, Pontifax Venture Capital, RA Capital, SR One, Bill Gates.
CellCentric has raised $155.0M across 2 funding rounds. Most recently, it raised $120.0M Series C in May 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2025 | $120.0M Series C | ARCH Venture Partners, Atlas Venture, Forbion, Krishna Yeshwant, HealthCap, INKEF Capital, Pfizer Venture Investments, Pontifax Venture Capital, RA Capital, SR One, Bill Gates | |
| Jul 1, 2024 | $35.0M Venture Round | ARCH Venture Partners, Atlas Venture, Krishna Yeshwant, Pfizer Venture Investments, RA Capital, SR One, Bill Gates |